TNF and sarcopenia: An incremental clinical benefit of blocking the catabolic effects on skeletal muscle tissue could be observed in IBD patients with sarcopenia treated by biologics including anti-TNF alpha agents and newer anti-interleukin, anti-integrin, and JAK inhibitors agents used for treatment of IBD.